journal of men's health
Volume 5, Issue 4 , Pages 342-349 , December 2008

Treatment for late-onset hypogonadism: the current situation in Japan

  • Akira Tsujimura, MD

      Affiliations

    • Department of Urology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan
    • Corresponding Author InformationCorresponding author.
    • ,
  • Akihiko Okuyama, MD

      Affiliations

    • Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

Received 23 July 2008 ,Accepted 16 October 2008.

References 

  1. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166:1660–1665
  2. Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM: International Society for the Study of the Aging Male. Aging Male. 2002;5:74–86
  3. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol. 2005;48:1–4
  4. Morley JE. Androgens and aging. Maturitas. 2001;38:61–71discussion 71–3
  5. Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM, et al. Endocrine aspects of sexual dysfunction in men. J Sex Med. 2004;1:69–81
  6. Morley JE, Perry HM. Androgen deficiency in aging men. Med Clin North Am. 1999;83:1279–1289vii.
  7. Vermeulen A. Andropause. Maturitas. 2000;34:5–15
  8. Morales A, Heaton JP, Carson CC. Andropause: a misnomer for a true clinical entity. J Urol. 2000;163:705–712
  9. Tsujimura A, Matsumiya K, Matsuoka Y, Takahashi T, Koga M, Iwasa A, et al. Bioavailable testosterone with age and erectile dysfunction. J Urol. 2003;170:2345–2347
  10. Namiki M, Akaza H, Shimazui T, Ito N, Iwamoto T, Baba K, et al. Clinical practice manual for late-onset hypogonadism syndrome. Int J Urol. 2008;15:377–388
  11. Morley JE, Kaiser FE. Sexual function with advancing age. Med Clin North Am. 1989;73:1483–1495
  12. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab. 1983;57:71–77
  13. Carani C, Bancroft J, Granata A, Del Rio G, Marrama P. Testosterone and erectile function, nocturnal penile tumescence and rigidity, and erectile response to visual erotic stimuli in hypogonadal and eugonadal men. Psychoneuroendocrinology. 1992;17:647–654
  14. Ahn HS, Park CM, Lee SW. The clinical relevance of sex hormone levels and sexual activity in the ageing male. BJU Int. 2002;89:526–530
  15. Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav. 1983;12:59–66
  16. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab. 1979;48:955–958
  17. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab. 1997;82:3793–3796
  18. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab. 2002;87:1467–1472
  19. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab. 1983;57:557–562
  20. Hwang TI, Chen HE, Tsai TF, Lin YC. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res. 2006;18:400–404
  21. Morley JE, Tariq SH. Sexuality and disease. Clin Geriatr Med. 2003;19:563–573
  22. Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl. 1992;13:297–304
  23. Nielsen J, Pelsen B, Sorensen K. Follow-up of 30 Klinefelter males treated with testosterone. Clin Genet. 1988;33:262–269
  24. Basaria S, Dobs AS. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging. 1999;15:131–142
  25. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1999;84:573–577
  26. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab. 1996;81:3578–3583
  27. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299:39–52
  28. Nair KS, Rizza RA, O’Brien P, Dhatariya K, Short KR, Nehra A, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355:1647–1659
  29. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57:141–147discussion 55–6
  30. Rabkin JG, Wagner GJ, Rabkin R. Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. J Clin Psychopharmacol. 1999;19:19–27
  31. Meier DE, Orwoll ES, Jones JM. Marked disparity between trabecular and cortical bone loss with age in healthy men. Measurement by vertebral computed tomography and radial photon absorptiometry. Ann Intern Med. 1984;101:605–612
  32. Orwoll ES, Oviatt SK, McClung MR, Deftos LJ, Sexton G. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med. 1990;112:29–34
  33. Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981;67:328–335
  34. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res. 1997;12:1833–1843
  35. Khosla S, Melton LJ, Atkinson EJ, O’Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86:3555–3561
  36. Khosla S, Melton LJ, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83:2266–2274
  37. Drinka PJ, Bauwens SF. Male osteopenia: a brief review. J Am Geriatr Soc. 1987;35:258–261
  38. Seeman E, Melton LJ, O’Fallon WM, Riggs BL. Risk factors for spinal osteoporosis in men. Am J Med. 1983;75:977–983
  39. Smith DA, Walker MS. Changes in plasma steroids and bone density in Klinefelter's syndrome. Calcif Tissue Res. 1977;22(Suppl):225–228
  40. Jackson JA, Riggs MW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci. 1992;304:4–8
  41. Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000;97:4279–4284
  42. Behre HM, von Eckardstein S, Kliesch S, Nieschlag E. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years. Clin Endocrinol (Oxf). 1999;50:629–635
  43. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56:M266–M272
  44. Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661–1667
  45. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:1966–1972
  46. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670–2677
  47. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism. 1970;19:653–663
  48. Kallman DA, Plato CC, Tobin JD. The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives. J Gerontol. 1990;45:M82–M88
  49. Shimokata H, Tobin JD, Muller DC, Elahi D, Coon PJ, Andres R. Studies in the distribution of body fat: I. Effects of age, sex, and obesity. J Gerontol. 1989;44:M66–73
  50. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999;107:123–136
  51. Abbasi AA, Mattson DE, Duthie EH, Wilson C, Sheldahl L, Sasse E, et al. Predictors of lean body mass and total adipose mass in community-dwelling elderly men and women. Am J Med Sci. 1998;315:188–193
  52. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282:E601–E607
  53. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab. 1996;81:3469–3475
  54. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88:2673–2681
  55. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab. 1996;81:3654–3662
  56. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci. 2003;58:618–625
  57. Wong FH, Pun KK, Wang C. Loss of bone mass in patients with Klinefelter's syndrome despite sufficient testosterone replacement. Osteoporos Int. 1993;3:3–7
  58. Gardner FH, Besa EC. Physiologic mechanisms and the hematopoietic effects of the androstanes and their derivatives. Curr Top Hematol. 1983;4:123–195
  59. Kennedy BJ, Gilbertsen AS. Increased erythropoiesis induced by androgenic-hormone therapy. N Engl J Med. 1957;256:719–726
  60. Tsujimura A, Matsumiya K, Takao T, Miyagawa Y, Takada S, Koga M, et al. Treatment with human chorionic gonadotropin for PADAM: a preliminary report. Aging Male. 2005;8:175–179
  61. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75:1092–1098
  62. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296:2351–2361
  63. Kalinchenko S, Vishnevskiy EL, Koval AN, Mskhalaya GJ, Saad F. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male. 2008;11:57–61
  64. Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A, et al. Androgen treatment of abdominally obese men. Obes Res. 1993;1:245–251
  65. Tsujimura A, Takada S, Matsuoka Y, Hirai T, Takao T, Miyagawa Y, et al. Is discontinuation of hormone replacement therapy possible for patients with late-onset hypogonadism?. Int J Urol. 2008;15(7):625–629
  66. Morgentaler A. Testosterone therapy for men at risk for or with history of prostate cancer. Curr Treat Options Oncol. 2006;7:363–369
  67. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006;50:935–939
  68. Morales A, Johnston B, Heaton JP, Lundie M. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol. 1997;157:849–854
  69. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab. 2004;89:5429–5434
  70. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med. 2007;4:497–501
  71. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84:3469–3478
  72. Schulte-Beerbuhl M, Nieschlag E. Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertil Steril. 1980;33:201–203
  73. Jones TH, Darne JF, McGarrigle HH. Diurnal rhythm of testosterone induced by human chorionic gonadotrophin (hCG) therapy in isolated hypogonadotrophic hypogonadism: a comparison between subcutaneous and intramuscular hCG administration. Eur J Endocrinol. 1994;131:173–178
  74. Finkel DM, Phillips JL, Snyder PJ. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. N Engl J Med. 1985;313:651–655
  75. Liu PY, Gebski VJ, Turner L, Conway AJ, Wishart SM, Handelsman DJ. Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men. Hum Reprod. 2002;17:625–633
  76. Amelar RD, Dubin L. Human chorionic gonadotrophin therapy in male infertility. JAMA. 1977;237:2423
  77. Schill WB, Jungst D, Unterburger P, Braun S. Combined hMG/hCG treatment in subfertile men with idiopathic normogonadotrophic oligozoospermia. Int J Androl. 1982;5:467–477
  78. Amano T, Imao T, Takemae K, Iwamoto T, Yamakawa K, Baba K, et al. Profile of serum testosterone levels after application of testosterone ointment (glowmin) and its clinical efficacy in late-onset hypogonadism patients. J Sex Med. 2008;5(7):1727–1736
  79. Comhaire FH. Andropause: hormone replacement therapy in the ageing male. Eur Urol. 2000;38:655–662
  80. Morley JE. Testosterone replacement and the physiologic aspects of aging in men. Mayo Clin Proc. 2000;75(Suppl):S83–S87
  81. Morley JE, Perry HM. Androgen treatment of male hypogonadism in older males. J Steroid Biochem Mol Biol. 2003;85:367–373
  82. T'Sjoen G, Goemaere S, De Meyere M, Kaufman JM. Perception of males’ aging symptoms, health and well-being in elderly community-dwelling men is not related to circulating androgen levels. Psychoneuroendocrinology. 2004;29:201–214
  83. T'Sjoen G, Feyen E, De Kuyper P, Comhaire F, Kaufman JM. Self-referred patients in an aging male clinic: much more than androgen deficiency alone. Aging Male. 2003;6:157–165
  84. Tsujimura A, Matsumiya K, Miyagawa Y, Takao T, Fujita K, Takada S, et al. Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. Int J Impot Res. 2005;17:259–263
  85. Miwa Y, Kaneda T, Yokoyama O. Correlation between the Aging Males’ Symptoms Scale and sex steroids, gonadotropins, dehydroepiandrosterone sulfate, and growth hormone levels in ambulatory men. J Sex Med. 2006;3:723–726
  86. Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241–4247
  87. Yoshida NM, Kumano H, Kuboki T. Does the Aging Males’ Symptoms scale assess major depressive disorder?: a pilot study. Maturitas. 2006;53:171–175
  88. Sato Y, Tanda H, Kato S, Onishi S, Nakajima H, Nanbu A, et al. Prevalence of major depressive disorder in self-referred patients in a late onset hypogonadism clinic. Int J Impot Res. 2007;19:407–410
  89. Chen JT, Shiraki M. Menopausal hot flash and calciotonin gene-related peptide; effect of Keishi-bukuryo-gan, a kampo medicine, related to plasma calciotonin gene-related peptide level. Maturitas. 2003;45:199–204
  90. Ushiroyama T, Ikeda A, Sakuma K, Ueki M. Changes in serum tumor necrosis factor (TNF-alpha) with kami-shoyo-san administration in depressed climacteric patients. Am J Chin Med. 2004;32:621–629
  91. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2003:CD003383.
  92. Shevtsov VA, Zholus BI, Shervarly VI, Vol'skij VB, Korovin YP, Khristich MP, et al. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine. 2003;10:95–105
  93. Pan B, Kato Y, Sengoku K, Takuma N, Niizeki N, Ishikawa M. Treatment of climacteric symptoms with herbal formulas of traditional Chinese medicine. Gynecol Obstet Invest. 2004;57:144–148
  94. Ushiroyama T, Ikeda A, Sakuma K, Ueki M. Chai-hu-gui-zhi-gan-jiang-tang regulates plasma interleukin-6 and soluble interleukin-6 receptor concentrations and improves depressed mood in climacteric women with insomnia. Am J Chin Med. 2005;33:703–711
  95. Tsujimura A, Takada S, Matsuoka Y, Nakayama J, Takao T, Miyagawa Y, et al. Clinical trial of treatment with saikokaryukotsuboreito for eugonadal patients with late-onset hypogonadism-related symptoms. Aging Male. 2008;11:95–99

PII: S1875-6867(08)00208-X

doi: 10.1016/j.jomh.2008.10.003

journal of men's health
Volume 5, Issue 4 , Pages 342-349 , December 2008

Article Tools

* Image Usage & Resolution